← Back to Search

Machine Perfusion

Liver Perfusion for Liver Transplant

N/A

Waitlist Available

Led By Cristiano Quintini, MD

Research Sponsored by The Cleveland Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months post-transplantation

Awards & highlights

Study Summary

This trial is testing whether a new method of preserving livers (NMP) before transplantation is better than the current standard (cold storage). NMP has been used before with promising results. If NMP is found to be better than cold storage, it would improve donor pool and outcomes for high risk ECD liver transplants.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months post-transplantation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months post-transplantation

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months post-transplantation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The rate of patient survival

The rate of primary non-function

Secondary outcome measures

The rate of Early Allograft Dysfunction post-transplantation

graft survival

peak Alanine Aminotransferase (ALT) in the first 7 days post-transplantation

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Normothermic Liver perfusionExperimental Treatment1 Intervention

This group has the liver grafts preserved using the Normothermic Liver perfusion Device

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

The Cleveland ClinicLead Sponsor

1,026 Previous Clinical Trials

1,366,046 Total Patients Enrolled

Cristiano Quintini, MDPrincipal Investigator - The Cleveland Clinic

Cleveland Clinic Hospital

University Di Bologna (Medical School)

3 Previous Clinical Trials

50 Total Patients Enrolled

Koji Hashimoto, MD, PhDPrincipal InvestigatorThe Cleveland Clinic

2 Previous Clinical Trials

25 Total Patients Enrolled

Media Library

Normothermic Liver Perfusion (Machine Perfusion) Clinical Trial Eligibility Overview. Trial Name: NCT03456284 — N/A

Liver Transplant Research Study Groups: Normothermic Liver perfusion

Liver Transplant Clinical Trial 2023: Normothermic Liver Perfusion Highlights & Side Effects. Trial Name: NCT03456284 — N/A

Normothermic Liver Perfusion (Machine Perfusion) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03456284 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there opportunities to join this medical research project currently?

"According to clinicaltrials.gov, this particular trial is not currently enrolling new patients; the original posting was on March 12th 2020 and it has since been updated last September 20 2022. Nevertheless, 52 other medical experiments are actively seeking participants at present time."

Answered by AI

Does this medical experiment accept participants aged 70 or above?

"To meet the criteria for this medical experiment, applicants must be aged between 18 and 75. Additionally, there are 5 trials specifically tailored to those below 18 years old, as well 49 geared towards seniors over 65."

Answered by AI

Are there any criteria that disqualify me from participating in this experiment?

"This clinical trial seeks 30 volunteers who are aged 18-75 and have undergone or will undergo orthoptic liver transplantation (OLT) for hepatocellular carcinoma. The ideal participants would be able to meet the following requirements: Milan Criteria, primary liver transplantation, age between 18-75 years at time of procedure, ability to follow study guidelines."

Answered by AI

What outcome are researchers hoping to realize in this experiment?

"This research protocol, which will span an approximate month post-transplantation, seeks to measure the occurrence of primary non-function. Secondary objectives include graft survival (allograft loss due to re-transplant or death), peak aspartate aminotransferase in 7 days (assessed via clinical laboratory test) and peak bilirubin levels within a week after transplantation (also measured through lab work)."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety and Feasibility of Normothermic Machine Perfusion to Preserve and Evaluate Orphan Livers

Koji Hashimoto 2020. "Safety and Feasibility of Normothermic Machine Perfusion to Preserve and Evaluate Orphan Livers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03456284.